Diabetes MODY tipo 3 de inicio precoz / Early onset MODY diabetes

La diabetes MODY (maturity onset diabetes of the Young) tipo 3 es una de las diabetes monogénicas y está causada por mutaciones en los genes del factor nuclear hepático 1 alfa (HNF1-α). Presentamos el caso de una niña de 6 años remitida para estudio de hiperglucemia, sin síntomas cardinales de diabetes tipo 1, y con antecedentes de diabetes en las dos generaciones anteriores. En el test de sobrecarga oral de glucosa (SOG) se objetivan cifras en rango diabético, hecho por frecuente una edad tan temprana. Se inicia tratamiento con insulina en un principio, y posteriormente con antidiabéticos orales, para disminuir el riesgo de afectación microvascular, que en la MODY tipo 3 es tan alto como en la diabetes tipo 1 (AU)

MODY diabetes (maturity onset diabetes of the yong), type 3, is one of the monogenic diabetes. It is caused by mutations in the hepatocyte nuclear factor (HNF)-q (alpha) gene mutations. We present the case of a 6 year old girl referred for a hyperglycemia study, with no core symptoms of type 1 diabetes, and with a background of diabetes in the two previous generations. In the glucose overload test (GOT), values were observed within the diabetic range, a rare event at such a young age. Treatment was initiated with insulin in the beginning and them with oral antidiabetics, to decrease the risk of microvascular involvement, which is as high as in type 1 diabetes in type 3 MODY (AU)

Diabetes de comienzo en la infancia tratada con sulfonilureas / Childhood-onset diabetes treated with sulphonylureas

La diabetes MODY (maturity onset diabetes of the young) tipo 3 pertenece al grupo de las diabetes monogénicas y está causada por mutaciones en los genes del factor nuclear hepático 1 alfa (HNF1-alfa). Aunque en la infancia la forma más frecuente es la tipo 2, en la población generales la tipo 3. Presentamos el caso de un niño de 12 años con hiperglucemia basal y posprandrial. No se refieren síntomas cardinales de diabetes tipo 1. Existen numerosos casos de diabetes en su familia. El péptido C es 1,13 ng/ml y los marcadores de autoinmunidad pancreática son negativos. Se encuentra una mutación en el gen HNF1-alfa en el paciente, así como en su padre y en su hermana. Se inicia tratamiento con glibenclamida a dosis de 2,5 mg/día para disminuir el riesgo de afectación microvascular, que en la diabetes MODY tipo 3 es tan alto como en la diabetes tipo 1. De ese modo, las glucemias se normalizan y la hemoglobina glucosilada se sitúa entre el 4,9 y el 5,6%. Nose observan efectos colaterales, salvo algunas hipoglucemias leves (AU)

MODY 3 type diabetes belongs to the group of monogenic diabetes and is caused by mutations in the gene for hepatocyte nuclear factor 1-alpha (HNF1-alpha). Although MODY 2 type diabetes is the most frequent form of MODY diabetes in childhood, type 3 is the most frequent in the general population. We report the case of a 12 year old child with basal and post-prandrial hyperglycaemia. Nocardinal symptoms of type 1 diabetes mellitus were present. There are numerous cases of diabetes in his family. C-Peptide was 1.13 ng/ml and pancreatic autoimmunity markers were negative. HNF-1alpha gene mutation was found in the patient as well as in his father and sister. Treatment with glibenclamide was started at a dose of 2.5 mg/day in order to reduce the risk of microvascular disease, as this as high in MODY 3 type diabetes as in type 1 diabetes mellitus. Blood glucose returned to normal and glycosylated haemoglobin was maintained between 4.9 and 5.6 %. Side-effects were not observed except some mild hypoglycaemias (AU)

[Childhood-onset diabetes treated with sulphonylureas]. / Diabetes de comienzo en la infancia tratada con sulfonilureas.

MODY 3 type diabetes belongs to the group of monogenic diabetes and is caused by mutations in the gene for hepatocyte nuclear factor 1-alpha (HNF1-alpha). Although MODY 2 type diabetes is the most frequent form of MODY diabetes in childhood, type 3 is the most frequent in the general population. We report the case of a 12 year old child with basal and post-prandrial hyperglycaemia. No cardinal symptoms of type 1 diabetes mellitus were present. There are numerous cases of diabetes in his family. C-Peptide was 1.13 ng/ml and pancreatic autoimmunity markers were negative. HNF-1alpha gene mutation was found in the patient as well as in his father and sister. Treatment with glibenclamide was started at a dose of 2.5 mg/day in order to reduce the risk of microvascular disease, as this as high in MODY 3 type diabetes as in type 1 diabetes mellitus. Blood glucose returned to normal and glycosylated haemoglobin was maintained between 4.9 and 5.6 %. Side-effects were not observed except some mild hypoglycaemias.